Pluronics are amphiphilic triblock copolymers composed of two hydrophilic poly (ethylene oxide) (PEO) chains linked via a central hydrophobic polypropylene oxide (PPO). Owing to their low molecular weight polymer and greater number of PEO segments, Pluronics induce micelle formation and gelation at critical micelle concentrations and temperatures. Pluronics F-68 and F-127 are the only United States (U.S.) FDA-approved classes of Pluronics and have been extensively used as materials for living bodies. Owing to the fascinating characteristics of Pluronics, many studies have suggested their role in biomedical applications, such as drug delivery systems, tissue regeneration scaffolders, and biosurfactants. As a result, various studies have been performed using Pluronics as a tool in nanomedicine and targeted delivery systems. This review sought to describe the delivery of therapeutic cargos using Pluronic F-68 and F-127-based cancer nanomedicines and their composites for combination therapy.

Ferrocene-containing nanoparticles show reversible redox activity that could trigger drug release mediated by reactive oxygen species (ROS). In this study, four ferrocene-containing polymers, comprising ferrocenylmethyl methacrylate (FMMA)–methacrylic acid (MA) random copolymers, i.e., poly(FMMA-r-MA), were synthesized via radical polymerization, resulting in self-assembled ferrocene nanoparticles (FNPs) with outstanding performance in environments in which ROS are present. These spherical FNPs have tunable diameters ranging from 270 nm to 180 nm and surface charges from −20 mV to −50 mV. Importantly, the diameters and surface charges of the FNPs changed dramatically after 2 h of post-treatment using 0.4 M hydrogen peroxide (H₂O₂) as the oxidant, indicating that the FNPs were highly ROS-sensitive. Furthermore, the controlled release of a model drug from the FNPs, reflected in the release profiles, indicates that these novel FNPs could be potentially used as drug carriers for the effective therapy of ROS-related diseases such as cancer and inflammation.

Cancer remains a major global health challenge. Traditional chemotherapy often results in side effects and drug resistance, necessitating the development of alternative treatment strategies such as gene therapy. Mesoporous silica nanoparticles (MSNs) offer many advantages as a gene delivery carrier, including high loading capacity, controlled drug release, and easy surface functionalization. MSNs are biodegradable and biocompatible, making them promising candidates for drug delivery applications. Recent studies demonstrating the use of MSNs for the delivery of therapeutic nucleic acids to cancer cells have been reviewed, along with their potential as a tool for cancer therapy. The major challenges and future interventions of MSNs as gene delivery carriers for cancer therapy are discussed.